The North America Rabies Vaccine Market would witness market growth of 4.0% CAGR during the forecast period (2023-2030).
The US market dominated the North America Rabies Vaccine Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $384.4 Million by 2030. The Canada market is experiencing a CAGR of 6.4% during (2023 - 2030). Additionally, The Mexico market would exhibit a CAGR of 5.4% during (2023 - 2030).
One key strategy for controlling rabies involves mass vaccination campaigns targeting domestic animals, particularly dogs. Dogs are the main reservoirs of the rabies virus, and widespread vaccination helps to interrupt the transmission cycle between humans and animals. Vaccinating a significant proportion of the canine population can dramatically reduce the incidence of rabies in animals and humans.
Oral rabies vaccination (ORV) is a unique and innovative approach to controlling the spread of rabies in wildlife populations. ORV involves distributing vaccine-laden baits in targeted areas to reach carnivorous wildlife species that may act as reservoirs for the virus. This method has been employed to prevent the spillover of rabies from wildlife to domestic animals and humans, contributing to the overall reduction of rabies cases.
Canada has been actively implementing wildlife rabies control programs, especially in regions where rabies is prevalent among wildlife species such as foxes, raccoons, and bats. The geographical coverage of ORV programs in Canada has expanded over time. Continuous efforts to reach a broader range of wildlife habitats contribute to more extensive control of rabies, reducing the risk of spillover to domestic animals and humans in Canada. ORV is often integrated with other control measures, such as surveillance, pet vaccination campaigns, and public health initiatives in Canada. The comprehensive approach maximizes the impact of rabies control efforts in Canada. Hence, the factors mentioned above will drive the regional market growth.
Free Valuable Insights: The Rabies Vaccine Market is Predict to reach USD 1.6 Billion by 2030, at a CAGR of 4.5%
Based on Prophylaxis Type, the market is segmented into Post-exposure Prophylaxis, and Pre-exposure prophylaxis. Based on End User, the market is segmented into Hospitals, Veterinary Clinics, and Others. Based on Application, the market is segmented into Human, and Animal. Based on Product Type, the market is segmented into Chick Embryo Cells Rabies Vaccine, Human Diploid Cell Vaccine, Vero cell rabies vaccine, and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
By Prophylaxis Type
By End User
By Application
By Product Type
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
